Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$3.83 +1.6%	$4.04	$3.35 ▼ $21.66	$99.09M	0.85	91,051 shs	115,055 shs
ITOS iTeos Therapeutics	$10.28 -0.3%	$9.41	$4.80 ▼ $18.13	$393.46M	1.49	702,886 shs	448,887 shs
SLDB Solid Biosciences	$5.58 +3.5%	$4.13	$2.41 ▼ $10.37	$432.53M	2.34	1.21 million shs	1.28 million shs
TECX Tectonic Therapeutic	$22.57 +5.3%	$21.48	$13.70 ▼ $61.07	$421.38M	3.17	190,394 shs	215,784 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	+1.07%	-3.83%	-14.90%	-13.93%	-82.05%
ITOS iTeos Therapeutics	-0.39%	+1.88%	+1.38%	+65.76%	-37.85%
SLDB Solid Biosciences	-1.46%	+2.86%	+19.51%	+113.89%	-37.03%
TECX Tectonic Therapeutic	-7.27%	+4.03%	-2.06%	+22.10%	+28.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	3.664 of 5 stars	3.6	5.0	3.6	0.8	1.3
ITOS iTeos Therapeutics	3.3066 of 5 stars	4.1	2.0	2.3	3.3	0.6
SLDB Solid Biosciences	3.4489 of 5 stars	4.6	1.0	3.2	2.5	0.6
TECX Tectonic Therapeutic	2.4884 of 5 stars	3.7	1.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.17	Buy	$22.50	487.47% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.86	54.25% Upside
SLDB Solid Biosciences	3.17	Buy	$15.10	170.61% Upside
TECX Tectonic Therapeutic	3.33	Buy	$83.60	270.40% Upside

Current Analyst Ratings Breakdown

Latest CTNM, TECX, SLDB, and ITOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/11/2025	TECX Tectonic Therapeutic	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	$7.66 per share	N/A
ITOS iTeos Therapeutics	$35M	11.24	N/A	N/A	$16.16 per share	0.64
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$3.43 per share	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$9.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)
TECX Tectonic Therapeutic	-$57.98M	-$7.31	N/A	N/A	N/A	N/A	-30.13%	-27.52%	8/13/2025 (Estimated)

Latest CTNM, TECX, SLDB, and ITOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TECX Tectonic Therapeutic	-$0.98	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	N/A	N/A	N/A	$7.50 million	N/A
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	21.47	21.47
ITOS iTeos Therapeutics	N/A	14.13	14.13
SLDB Solid Biosciences	N/A	10.89	10.89
TECX Tectonic Therapeutic	N/A	22.92	22.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
ITOS iTeos Therapeutics	97.16%
SLDB Solid Biosciences	81.46%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
ITOS iTeos Therapeutics	12.50%
SLDB Solid Biosciences	13.63%
TECX Tectonic Therapeutic	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable
SLDB Solid Biosciences	100	77.52 million	66.95 million	Optionable
TECX Tectonic Therapeutic	120	18.67 million	16.96 million	N/A

CTNM, TECX, SLDB, and ITOS Headlines

Recent News About These Companies

Tectonic Therapeutic (NASDAQ:TECX) Rating Increased to Hold at Wall Street Zen

July 6, 2025 | americanbankingnews.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $83.60 Average PT from Analysts

July 6, 2025 | americanbankingnews.com

Tectonic Therapeutic (NASDAQ:TECX) Upgraded to "Hold" at Wall Street Zen

July 5, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Buy" from Brokerages

July 3, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution - Nasdaq

July 1, 2025 | nasdaq.com

Tectonic Therapeutic joins Russell 3000 index

June 30, 2025 | msn.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution

June 30, 2025 | quiverquant.comQ

Tectonic Therapeutic Joins Russell 3000® Index

June 30, 2025 | globenewswire.com

Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating

June 25, 2025 | msn.com

Tectonic Therapeutic (NASDAQ:TECX) Stock Rating Lowered by Wall Street Zen

June 21, 2025 | marketbeat.com

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

June 15, 2025 | finance.yahoo.com

Tectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock News

June 10, 2025 | gurufocus.com

LifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform Recommendation

June 7, 2025 | msn.com

Tectonic Therapeutic Holds 2025 Annual Stockholders Meeting

June 6, 2025 | tipranks.com

Tectonic Therapeutic (TECX) Receives Outperform Rating and $87 Price Target | TECX Stock News

June 5, 2025 | gurufocus.com

Tectonic Therapeutic Reports Q1 2025 Financial Results

May 30, 2025 | tipranks.com

Promising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45

May 22, 2025 | tipranks.com

Tectonic Therapeutic Announces Phase 1b Trial Results

May 19, 2025 | tipranks.com

Promising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic Therapeutic

May 19, 2025 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)

May 17, 2025 | theglobeandmail.com

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in ...

May 17, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
By Leo Miller | June 18, 2025
View Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

CTNM, TECX, SLDB, and ITOS Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$3.83 +0.06 (+1.59%)

Closing price 04:00 PM Eastern

Extended Trading

$3.84 +0.00 (+0.13%)

As of 04:04 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

iTeos Therapeutics NASDAQ:ITOS

$10.28 -0.03 (-0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$10.28 +0.01 (+0.05%)

As of 04:21 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Solid Biosciences NASDAQ:SLDB

$5.58 +0.19 (+3.53%)

Closing price 04:00 PM Eastern

Extended Trading

$5.57 -0.01 (-0.18%)

As of 07:46 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Tectonic Therapeutic NASDAQ:TECX

$22.57 +1.13 (+5.27%)

Closing price 04:00 PM Eastern

Extended Trading

$22.20 -0.37 (-1.64%)

As of 04:57 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time